| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Development Officer | COO and Chief Medical Officer
2 companies
Dragan Cicic is SVP, Chief Development Officer at SLS and has filed Form 4s across 2 companies. Dragan Cicic's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.9M at current prices.
The biggest single holding is SLS (~$4.9M) as SVP, Chief Development Officer.
Dragan Cicic has 7 Form 4 filings on record from May 2015 to January 2026, across 2 companies: SVP, Chief Development Officer at SELLAS Life Sciences Group (SLS), 2024–2026; Chief Technology Officer at Actinium Pharmaceuticals (ATNM), 2015–2017.
The 11 reported transactions were 4 option or other derivative awards, 3 stock awards, 2 other transactions and 1 tax withholding, plus smaller numbers of other types.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria